Turhan TOGAN, Özlem Kurt AZAP, Serdar Ö. KARAMAN, Hande ARSLAN

Toplumda dışkıda genişlemiş-spektrumlu beta laktamaz salgılayan escherichia coli ve klebsiella spp.Suşların sıklığının araştırılması

Aim: Community-acquired infections caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria are an emerging problem. Digestive tract colonization is a prerequisite for infections by ESBL-producing microorganisms. The aim of this study was to determine the prevalence of and risk factors for fecal carriage of ESBL-producing Escherichia coli (E. coli) or Klebsiella spp. in the community. Materials and Methods: A total of 928 stool samples admitted to the laboratory during a four-month period were included in the study. Samples were diluted in saline and cultured in two EMB agar plates supplemented with either 1 μg/ml cefotaxime or 1 μg/ml ceftazidime. All isolates that grew were identified to the species level. E. coli and Klebsiella spp. strains were tested for ESBL production with ceftazidime and ceftazidimeclavulanate discs according to the Clinical and Laboratory Standards Institute (CLSI) Guideline. Results: Of the 928 stool samples included, 133 (14%) were isolated from inpatients and 795 (86%) from outpatients. Sixty-three (47.3%) of 133 hospitalized and 121 (15.2%) of 795 outpatients harbored ESBLproducing E. coli and Klebsiella spp. (P = 0.000). Chronic hepatic failure (OR: 8.7, CI: 1.65-46.12; P = 0.011) and recent antibiotic use (OR: 4.4, CI: 1.76-11.16; P = 0.002) were found to be associated with ESBL positivity for the hospitalized patients. Recent antibiotic use (OR: 2.8, CI: 1.61-5.12; P = 0.000) was found to be the only independent variable associated with ESBL positivity for the outpatients. Conclusions: The high prevalence (15.2%) of fecal carriage of ESBL-producing bacteria in the community warrants further study in this field including the consequences of this colonization in the hospital setting.

Risk factors for fecal carriage of extended-spectrum beta-lactamase pruducing escherichia coll and klebsiella spp.in the community

PDF

___

1. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951.
2. Knothe H, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-317.
3. Quinn JP, Miyashiro D, Sham D, Flamm R, Bush K. Novel plasmidmediated beta-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33: 1451-1456.
4. Harris AD, Nemoy L, Johnson JA, Carnahan AM, Smith DL, Standiford H et al. Co-carriage of vancomycin-resistant enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Inf Control Hosp Epidemiol 2004; 25: 105-108.
5. Pitout JDD, Nordman P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-59.
6. Cormican M, Morris D, Corbett-Feeney G, Flynn J. Extendedspectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317-319.
7. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W et al. Risk factors for the development of extended-spectrum beta-lactamase producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163-167.
8. Moustaoui N, Soukri A, Elmdaghri N, Boudouma M, Benbachir M. Molecular biology of extended-spectrum beta-lactamase producing Enterobacteriaceae responsible for digestive tract colonization. J Hosp Infect 2004; 57: 202-208.
9. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58.
10. Lucet JC, Chevret S, Decre DI. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996; 22: 430-436.
11. Moustaoui N, Bensghir R, Mjahed K, Hakim K, Aimhand R, Boudouma M et al. Digestive tract colonization with extendedspectrum beta-lactamase producing Enterobacteriaceae in a surgical intensive care unit in Casablanca. J Hosp Infect 2000; 46: 238-240.
12. Valverde A, Teresa MC, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-4775.
13. Millar MR, Walsh TR, Linton JC, Zhang S, Leeming JP, Bennett PM and the ALSPAC Study Team. J Antimicrob Chemother 2001; 47: 605-610.
14. Clinical and Laboratory Standards Institute (CLSI), formerly NCCLS. Performance Standards for Antimicrobial Susceptibility Testing; Fifteenth Informational Supplement. CLSI/NCCLS document M100-S15. Wayne, PA: CLSI, 2005.
15. Smith DL, Dushoff J, Perencevich EN, Harris AD, Levin SA. Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem. Proc Natl Acad Sci USA 2004; 101: 3709-3714.
16. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis 2001; 33(Suppl 3): S161-169.
17. Bonten MJ, Slaughter S, Ambergen AW, Hayden MK, Voorhis JV, Nathan C et al. The role of “colonization pressure” in the spread of vancomycin-resistant enterococci: an important infection-control variable. Arch Intern Med 1998; 158: 1127-1132.
18. Brinas L, Zarazaga M, Saenz Y, Ruiz-Larrea F, Torres C. ß-Lactamases in ampicillin-resistant Escherichia coli isolates from foods, humans, and healthy animals. Antimicrob Agents Chemother 2002; 46: 3156-3163.
19. Österblad M, Hakanen A, Manninen R, Leistevuo T, Peltonenn R, Meurman O et al. A between-species comparison of antimicrobial resistance in Enterobacteria in fecal flora. Antimicrob Agents Chemother 2000; 44: 1479-1484.
20. Mirelis B, Navarro F, Miro E, Mesa RJ, Coll P, Prats G. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 2003; 9: 1024-1025.
21. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517-523.
22. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
23. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39: 75-80.
24. Gniadkowski M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect Dis 2001; 7: 597-608.
25. Arslan H, Azap ÖK, Ergönül Ö, Timurkaynak F, on behalf of the Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914-918.